Bio-Techne Launches Cell and Gene Therapy Portfolio

MINNEAPOLIS /PRNewswire/ -- Bio-Techne announces the launch of their cell and gene therapy portfolio. As a leading manufacturer of GMP-grade ancillary materials and automated instrumentation, Bio-Techne is uniquely able to offer solutions that advance the translation of cell and gene therapies, from discovery-level research to the optimization of cell therapy manufacturing unit operations. Bio-Techne's multi-brand portfolio of cell and gene therapy tools can now be viewed at www.bio-techne.com.

Bio-Techne's cell and gene therapy portfolio includes GMP cytokines and growth factors, GMP small molecules, GMP media, and high-quality antibodies for flow cytometry and immunocytochemical characterization. In addition, Bio-Techne has focused on developing innovative solutions that optimize and simplify cell therapy manufacturing, including their pioneering technologies, Cloudz™ Cell Activation Kits and the Simple Plex immunoassays. These technologies are designed to expedite cell expansion and improve product quality control, respectively.

"We are thrilled to now have our tools for cell and gene therapy organized on the Bio-Techne website under a unifying workflow," commented Dave Eansor, President of Bio-Techne's Protein Sciences Segment. "The website provides a vision of how our company can uniquely move this field forward, at both the therapeutic and research level. That vision is to provide simple and flexible solutions that streamline the delivery of effective therapies to patients.  The portfolio displayed on the website is also an excellent showcase of Bio-Techne's current pioneering cell therapy manufacturing solutions."


The Bio-Techne cell and gene therapy portfolio is currently on display at Phacilitate – Cell and Gene Therapy World from January 22 – 25th, 2019 in Miami, Florida. On Wednesday, January 25th, Dr. Joy Aho, Senior Product Manager for Cell and Gene Therapy, will present on "Optimizing Workflows for Ex Vivo Cell Therapy Manufacturing" (Wednesday, January 25th2:20-2:35 pm) and Nithya Jesuraj, R&D Manager for Cell and Gene Therapy, will present a poster on "Optimizing Cell Activation, Cytokine Stimulation, and Bioreactor Systems for Efficient Ex Vivo Expansion of Human T Cells" (Wednesday January 25th6-7:30 pm).

 

CONTACT: Dave Eansor, President, Protein Sciences Segment, 612-379-2956

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.